Latest Headlines

Latest Headlines

Scripps scientists ID weakness-attacking antibodies in pursuit of HIV vaccine

A team at The Scripps Research Institute in La Jolla this week said they have identified four antibodies to target weaknesses in HIV, touting an "important advance" in HIV vaccine research that could assist in developing a vaccine.

MabSpace gets $15M as Lilly Asian Ventures bets on immune approach

Suzhou-based MabSpace Biosciences has raised $15 million in Series A funding from Lilly Asia Ventures to develop the biotech's technology for antibodies that break the tolerance of the immune system.

Eli Lilly collaborates with ImaginAb on T cell cancer research

After signing on for a full lineup of combination drug studies with leading checkpoint inhibitors from Merck, AstraZeneca and Bristol-Myers Squibb, Eli Lilly is headed to the preclinical drawing board with a new collaboration to use ImaginAb's immune imaging agent IAB22M2C to study new T cell therapies for fighting cancer.

Lilly signs a $1B deal to deepen its oncology ties with China's Innovent

Eli Lilly has expanded its R&D partnership with China's Innovent Biologics, bringing in three potential immunotherapies for cancer and adding another $1 billion in potential value to the existing alliance.

Roche picks up a new autoimmune drug with $580M Adheron deal

Roche is investing in an early-stage project that takes a novel approach to treating autoimmune diseases, agreeing to pay up to $580 million for California's Adheron Therapeutics.

Sorrento launches another joint venture with a $170M cancer deal

Sorrento Therapeutics, among the constellation of companies associated with billionaire Patrick Soon-Shiong, is again widening its R&D mission with a joint venture, teaming up with a California cancer center on some novel antibody technology.

Google, OrbiMed buy into Alector's novel take on Alzheimer's with a $32M round

Under-the-radar biotech startup Alector raised $32 million in Series C funds to support its early-stage work in neurodegenerative disease, recruiting some high-profile investors as it develops a novel approach to brain-destroying disorders.

Amgen bets up to $1.7B on Xencor's antibody technology

Amgen is teaming up with Xencor through a heavily back-loaded deal worth as much as $1.7 billion, collaborating on 6 early-stage programs in immuno-oncology and inflammation.

Regeneron team IDs a candidate for ultra-rare bone disease

Back at the beginning of 2014, a fast-growing Regeneron revealed that it had been building a new genetics research center that would zero in on carefully targeted diseases as it built new drug development programs from the ground up. Eighteen months later the big biotech says the effort--led by some top researchers wooed in to run the operation--has paid off with a clear target for a rare genetic bone disease. And they have an antibody in preclinical testing that could correct the disorder.

Amgen's bone drug beats Lilly's Forteo in a Phase III osteoporosis trial

Amgen's investigational bone-growing drug met its main goal in a late-stage trial, clearing its first Phase III hurdle by besting an Eli Lilly blockbuster for osteoporosis.